India Bans 16 Drug Combos, Including Paracetamol Mix, Over Health Risks
India Bans 16 Drug Combos, Including Paracetamol Mix, Over Health Risks
India's Union Health Ministry bans 16 fixed-dose combination (FDC) drugs, including certain painkillers and a Paracetamol mix, citing lack of therapeutic justification and potential patient risks. This crucial move aims
In a significant move to safeguard public health, the Indian government has announced an immediate ban on the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs across the country. The Union Health Ministry declared these medicines lack therapeutic justification and could pose risks to patients, making their removal from the market essential.
FDC drugs are formulations that contain a combination of two or more active pharmaceutical ingredients (APIs) in a fixed ratio. The Ministry's decision comes after a thorough review, conducted in compliance with directions from the Supreme Court. The Drugs Technical Advisory Board (DTAB) played a crucial role in this process, forming an expert committee to scrutinize various drug combinations. This committee was tasked with identifying drugs deemed irrational, therapeutically unjustified, or potentially harmful to users.
The rationale behind the ban is clear: the prohibited combinations were found to "lack therapeutic justification" and were "not considered beneficial" when weighed against the potential risks involved. This stringent evaluation ensures that only scientifically validated and safe medicines remain accessible to the public.
The banned formulations span several therapeutic categories. These include certain dermatological preparations, analgesic (painkiller) medicines, and antispasmodic (muscle relaxant) drugs, as well as specific antibiotic-based combinations. Notably, combinations such as Acetyl Salicylic Acid with Ethoheptazine, and certain Paracetamol mixes, are among those now prohibited.
To ensure the immediate and effective implementation of this ban, all state drug controllers, regulatory authorities, and enforcement agencies have been directed to strictly adhere to the new notifications. This nationwide directive underscores the government's commitment to maintaining drug safety and quality standards across India, protecting citizens from potentially unsafe pharmaceutical products.
